Evidence map›Paper›PMID 38445424›Full record

ArticleLa Tunisie medicale2023

Abir Boussetta, Rihab Fatnassi, Manel Jellouli, Rym Maamouri, Ridha Mrad, Tahar Gargah, Asma Omezzine

Open access · greenAbstract readEnglish Abstract
In one paragraph

Article in La Tunisie medicale, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 1 citations in OpenAlex.

  1. Global access to management of primary hyperoxaluria: a survey on behalf of OxalEurope, G&K Working Group of the ERA and ESPN.Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association · 2025
    Article
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 2 institutions in 1 country.

Abir BoussettaDepartment of Pediatric Nephrology, Charles Nicolle Hospital.
Rihab FatnassiDepartment of Pediatric Nephrology, Charles Nicolle Hospital.
Manel JellouliDepartment of Pediatric Nephrology, Charles Nicolle Hospital.
Rym MaamouriDepartment of Ophthalmology, Habib Thameur Hospital.
Ridha MradDepartment of Hereditary and Congenital Diseases, Charles Nicolle Hospital.
Tahar GargahDepartment of Pediatric Nephrology, Charles Nicolle Hospital.
Asma OmezzineDepartment of Biochemistry, Sahloul Hospital, Tunisia.
Faculté de médecine de TunisTunis El Manar University · TN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

introductionThere are three types of primary hyperoxaluria, with type 1 considered the most severe.

aimTo analyze the clinical, genetic, and evolutionary characteristics of type 1 primary hyperoxaluria with pediatric onset.

methodsThis was a retrospective, descriptive study that included Tunisian children under the age of 18 at the time of diagnosis over a period of 25 years (January 1, 1996, to December 31, 2022).

resultsThirty-five patients were included, with a mean age of 4.1 years. The most common presenting circumstances of the disease were nephrolithiasis and end-stage renal failure. The average serum creatinine level was 225.42 µmol/l. Five mutations were identified, with the p.Ile244Thr mutation being the most prevalent. Nephrocalcinosis, surgical intervention, and a creatinine level ≥57 µmol/l were predictive of progression to end-stage renal failure. The infantile form was predictive of mortality.

conclusionsScreening for the disease would improve the prognosis of this condition.

Indexed as

Hyperoxaluria, PrimaryKidney Failure, ChronicAdultChildChild, PreschoolHumansMutationRetrospective Studies

Identifiers

PMID38445424
PMCPMC11217970
OpenAlexW4394740331

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.